SCHEDULE: Pfizer Discloses 3.3% Stake in ORIC Pharmaceuticals
Beneficial Ownership Filing
Pfizer Inc. has reported a beneficial ownership of 3,442,940 shares, representing 3.3% of the outstanding common stock of ORIC Pharmaceuticals, Inc. as of March 31, 2026.
Summary
- Pfizer Inc. has filed a Schedule 13G, indicating it beneficially owns 3,442,940 shares of ORIC Pharmaceuticals, Inc. common stock.
- This holding represents 3.3% of the total outstanding shares of ORIC Pharmaceuticals as of March 31, 2026.
- The filing is an amendment (Amendment No. 1) to a previous filing.
- Pfizer Inc. has sole voting power and sole dispositive power over these shares.
- The filing date for this statement is March 31, 2026, with the signature date being May 12, 2026.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership by a major investor without additional strategic or financial commentary.
Positives
- Pfizer Inc. has acquired a significant minority stake in ORIC Pharmaceuticals, potentially indicating strategic interest or investment.
- Pfizer Inc. holds sole voting and dispositive power, suggesting clear control over its investment decisions regarding these shares.
Risks
- The filing does not detail the specific purpose of Pfizer's investment, leaving potential strategic intentions open to speculation.
- As a Schedule 13G filing, it indicates passive investment, meaning Pfizer is not seeking to influence or control ORIC Pharmaceuticals' management or policies.
Future Outlook
This filing is a disclosure of current ownership and does not contain forward-looking statements or guidance from ORIC Pharmaceuticals.
Industry Context
StockSavvy.ai notes that significant stake acquisitions by large pharmaceutical companies like Pfizer in smaller biotech firms often signal potential future collaborations, licensing deals, or even acquisition targets within the competitive biopharmaceutical landscape.
Stakeholder Impact
- Shareholders of ORIC Pharmaceuticals: The filing indicates a significant investment by Pfizer, which could be perceived positively as validation of the company's potential, but also raises questions about future strategic direction.
- Shareholders of Pfizer: This filing represents a minor investment by Pfizer, unlikely to have a material impact on Pfizer's overall financial performance or stock price in the short term.
Key Dates
| Date | Description |
|---|---|
| 03/31/2026 | Date of Event Which Requires Filing of this Statement |
| 04/27/2026 | Date as of which total shares of common stock outstanding were reported on ORIC Pharmaceuticals' Form 10-Q. |
| 05/04/2026 | Date ORIC Pharmaceuticals filed its quarterly report on Form 10-Q for the period ended March 31, 2026. |
| 05/12/2026 | Date of signature on the Schedule 13G filing. |
Keywords
Pfizer Inc., ORIC Pharmaceuticals, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment, 3.3%
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.